Rotary Club of Catawba Valley supports Pink Heals hickoryrecord.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hickoryrecord.com Daily Mail and Mail on Sunday newspapers.
Date Time
Researchers aim to end chronic pain in MS patients by finding its starting point
A newly announced grant from the MS Society is helping researchers at the University of Alberta to better understand the underlying cause of chronic pain that afflicts an estimated half of people with multiple sclerosis, and how to eradicate it.
Bradley Kerr and his team are looking in particular at the peripheral nervous system, which involves all the nerves in the body outside of the brain and spinal cord. The researchers will use the funding, worth just under $300,000 over three years, to study one of the most common types of chronic neuropathic pain in MS, trigeminal neuralgia a facial pain that can be devastating for sufferers.
Emerging Australia oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced a license agreement for its lead pipeline candidate.
(1)
TOKYO, Mar 5, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data from its Alzheimer s disease (AD) and dementia pipeline, including the investigational anti-amyloid beta (Aß) protofibril antibody lecanemab (Development Code: BAN2401), will be presented at the 15th International Conference on Alzheimer s and Parkinson s Disease (AD/PD2021) to be held virtually from March 9 to 14, 2021.
Regarding lecanemab, preliminary analysis results of changes in brain-Aß amounts as observed in subjects of the ongoing open-label extension (OLE) of the Phase II study (Study 201) will be presented orally.
Regarding aducanumab, for which applications are currently underway in the U.S., Europe and Japan, Biogen Inc. will conduct presentations on the correlation of amyloid PET and cerebrospinal fluid (CSF) biomarkers in the Phase III studies (EMERGE/ENGAGE), as well as evaluations of the safety and efficacy of aducanumab in early AD. Lecanemab and aducanumab are being j